Immunotherapy with programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade has shown low response rates in liver cancer patients, with the underlying mechanisms unclear. To decipher a specific impact of the liver microenvironment, we compared the effects of anti-PD-L1 antibody (αPD-L1) blockade on the same tumor grown s.c. or in the liver.

中文翻译：

---

通过克服小鼠肝脏免疫耐受增强程序性死亡配体1抗体对转移性肝癌的治疗效果

程序性细胞死亡 1 (PD-1)/程序性死亡配体 1 (PD-L1) 阻断的免疫治疗在肝癌患者中显示出较低的反应率，其潜在机制尚不清楚。为了解读肝脏微环境的具体影响，我们比较了抗 PD-L1 抗体 (αPD-L1) 阻断对皮下或肝脏中生长的同一肿瘤的影响。